Glaxo's Witty calls for £1B U.K. R&D fund

U.K. researchers are senselessly competing with each other for funds, GlaxoSmithKline ($GSK) CEO Andrew Witty said, and the time has come for the government to pony up £1 billion ($1.6 billion) and dedicate it to collaborative R&D across the country's academic institutions. The CEO, who also serves as chancellor of Nottingham University, said Britain needs to move beyond its provincial funding model and focus on research areas where the country's scientists have a chance for commercial breakthroughs. Article

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.